BTIG Research Reaffirms “Buy” Rating for Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical (NASDAQ:ISRG)‘s stock had its “buy” rating restated by BTIG Research in a report released on Wednesday, Benzinga reports. They currently have a $454.00 target price on the medical equipment provider’s stock. BTIG Research‘s price target points to a potential upside of 6.58% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. Mizuho set a $415.00 target price on Intuitive Surgical in a research note on Tuesday, October 13th. UBS Group reissued a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. JPMorgan Chase & Co. cut their target price on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a research note on Friday, July 17th. Citigroup cut their target price on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Finally, Barclays reissued an “overweight” rating and set a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a research note on Wednesday. Twenty-five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $497.39.

Intuitive Surgical Stock Down 2.7%

ISRG opened at $425.97 on Wednesday. The business has a 50 day moving average price of $392.96 and a two-hundred day moving average price of $409.06. The company has a market cap of $150.48 billion, a PE ratio of 48.97, a P/E/G ratio of 3.27 and a beta of 1.46. Intuitive Surgical has a 52 week low of $328.57 and a 52 week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, beating the consensus estimate of $2.65 by $0.35. The firm had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The firm’s revenue was up 21.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.40 EPS. As a group, sell-side analysts expect that Intuitive Surgical will post 8.87 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Mark Brosius sold 77 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $375.57, for a total value of $28,918.89. Following the sale, the executive vice president directly owned 881 shares of the company’s stock, valued at approximately $330,877.17. This represents a 8.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 72 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total transaction of $28,303.20. Following the transaction, the director owned 179 shares of the company’s stock, valued at $70,364.90. This trade represents a 28.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is owned by insiders.

Institutional Trading of Intuitive Surgical

Several institutional investors and hedge funds have recently modified their holdings of ISRG. Bank of America Corp DE raised its stake in Intuitive Surgical by 3.3% in the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after purchasing an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Intuitive Surgical in the 2nd quarter valued at about $1,335,753,000. Amundi boosted its stake in shares of Intuitive Surgical by 8.6% during the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after purchasing an additional 193,096 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after purchasing an additional 1,027,475 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Intuitive Surgical by 13.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider’s stock worth $804,431,000 after purchasing an additional 211,237 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical reported third-quarter revenue of $3.05 billion, up 21.7% year over year and above the approximately $2.91 billion analyst estimate. Adjusted earnings of $3.00 per share also exceeded consensus, while worldwide procedures increased about 15% and da Vinci system placements rose to 546 from 427 a year earlier. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Several analysts remain constructive: Bernstein reaffirmed a Buy rating with a $685 price target, BTIG maintained Buy, Baird raised its target to $550, and Erste Group upgraded the stock to Buy. These actions reflect confidence in robotic-surgery demand, the da Vinci platform and Intuitive’s innovation pipeline. Analyst Ratings and Price Target
• Neutral Sentiment: RBC Capital retained its Outperform rating while lowering its target to $550 from $575. Raymond James also trimmed its target to $480 from $483, while Mizuho cut its target to $400 and kept a Neutral rating, creating a mixed analyst picture. RBC Capital Price Target Update
• Negative Sentiment: GAAP profit fell to $1.49 per share because Intuitive recorded a $450 million pretax charge, or approximately $0.99 per share after tax, tied to a proposed antitrust settlement. The settlement still requires court approval, adding legal and earnings uncertainty. Antitrust Settlement Charge
• Negative Sentiment: Management narrowed its 2026 global da Vinci procedure-growth forecast to 14%-15%. Planned actions to reduce per-procedure instrument costs by roughly 3%-5% may support long-term adoption but could pressure near-term revenue and margins. Reports also highlighted a slowdown in U.S. procedure growth, which amplified the market’s reaction. Intuitive Narrows Procedure Growth Outlook

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.